Preoperative Chemoradiotherapy for Resectable Gastric Cancer
Trevor Leong,B Mark Smithers,Michael Michael,Karin Haustermans,Rebecca Wong,Val Gebski,Rachel L O'Connell,John Zalcberg,Alex Boussioutas,Michael Findlay,David Willis,Alisha Moore,William K Murray,Florian Lordick,Chris O'Callaghan,Carol Swallow,Gail Darling,Danielle Miller,Andrew Strickland,Moishe Liberman,Laurent Mineur,John Simes,Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, and Canadian Cancer Trials Group,Regina Tse,Andrew Kneebone,Jayasingham Jayamohan,Stephen Thompson,Mark Lee,Lorraine Chantrill,Yaw Chin,Mahesh Kumar,Ratnesh Srivastav,Sue Anne McLachlan,Maitham Mathlum,Niall Tebbutt,Philip Tran,Mark Smithers,Chris Karapetis,Colin Tang,Rosemary Young,Mark Bell,Dean Harris,Chris Jackson,Hermann Van De Vyer,Christoph Schulz,Christine Belletier,Begona Navalpotro,Irena Oblak,Milan Vosmik,Wim Demey,Myroslav Lutsyk,Nicolas Christian,Jozef Janssens,Thierry Conroy,Philippe Vergauwe,Kim Stefano,Hassan Rezaei Kalantari,Marc Peeters,Guy Deboever,Lothar Mueller,Ravit Geva,Guido Hildebrandt,Maica Del Carman Galán Guzmán,Daniel Zips,Tania Fleitas Kanonnikoff,Axel Stang,Jurgen Krauter,Joris Arts,Monica Caro,Haj Chalchal,Gregory Knight,Richard A Malthaner,Eric Frechette,Shahid Ahmed,Aamed Mahmud,Cathy Menkarios,Juhu Kamra,Sebastien Gilbert,Scott Berry,Mark Doherty,Michael Raphael,Frederic Lemay,Mohammed Akra,Petr Kavan,Ashley Douglas,Rachel O'Connell,Gillian Worden,Emile Peponoulas,Carolina Fernandez,Alan Coates,Howard Gurney,Ian Marschner,Katrina Sharples,Viet Do,Michael Friedlander,Peter Grimison,Doug Taipin,Charlotte Lemech,Hira Saud,Evonne Tim,Christine Aiken,Tara Flores,Russell Conley,Tim Price,Kin Jin Cheung,Carolina Fernandes,Axelle Nzokirantevye
DOI: https://doi.org/10.1056/NEJMoa2405195
2024-11-14
Abstract:Background: In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone. Methods: We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control). In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel both before and after surgery; the preoperative-chemoradiotherapy group also received chemoradiotherapy (45 Gy in 25 fractions of radiation, plus fluorouracil infusion). The primary end point was overall survival, and secondary end points included progression-free survival, pathological complete response, toxic effects, and quality of life. Results: A total of 574 patients underwent randomization at 70 sites in Australasia, Canada, and Europe: 286 to the preoperative-chemoradiotherapy group and 288 to the perioperative-chemotherapy group. A higher percentage of patients in the preoperative-chemoradiotherapy group than in the perioperative-chemotherapy group had a pathological complete response (17% vs. 8%) and greater tumor downstaging after resection. At a median follow-up of 67 months, no significant between-group differences in overall survival or progression-free survival were noted. The median overall survival was 46 months with preoperative chemoradiotherapy and 49 months with perioperative chemotherapy (hazard ratio for death, 1.05; 95% confidence interval, 0.83 to 1.31), and the median progression-free survival was 31 months and 32 months, respectively. Treatment-related toxic effects were similar in the two groups. Conclusions: The addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone among patients with resectable gastric and gastroesophageal junction adenocarcinoma. (Funded by the National Health and Medical Research Council and others; TOPGEAR ClinicalTrials.gov number, NCT01924819.).